Peptide and method for reducing the phosphate requirement and excretion from farm animals

ABSTRACT

Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Patent ApplicationNo. 61/551,749, filed Oct. 26, 2011, which is incorporated herein byreference in its entirety.

INCORPORATION OF SEQUENCE LISTING

A paper copy of the Sequence Listing and a computer readable form of thesequence containing the file named “28243-171 (P120032US02)_ST25.txt”,which is 8,764 bytes in size (as measured in MS-DOS), are providedherein and are herein incorporated by reference. This Sequence Listingconsists of SEQ ID NOS:1-48.

BACKGROUND OF THE DISCLOSURE

The present disclosure relates generally to a method of alteringmetabolism of a dietary nutrient (e.g., phosphate) in livestock via anantibody, which increases the absorption and retention of the dietarynutrient, thereby decreasing its excretion into the environment.

Fibroblast growth factor-23 (FGF-23) has recently been identified as amajor player in phosphate homeostasis. (See Liu and Quarles, “HowFibroblast Growth Factor 23 works,” J. Am. Soc. Nephrol. 18:1637-1647(2007) and Yamashita et al., “Identification of a novel fibroblastgrowth factor, FGF-23, preferentially expressed in the ventrolateralthalamic nucleus of the brain,” Biochem. Biophys. Res. Commun.277:494-498 (2000)). FGF-23 is predominately produced by osteocytes inbone, and its principal actions are to inhibit sodium-dependentphosphate reabsorption and 1α-hydroxylase activity in the kidney,leading to increased phosphate excretion and low circulating 1,25(OH)₂D₃levels (hence reduced intestinal absorption of phosphate). (See Liu andQuarles, “How Fibroblast Growth Factor 23 works,” J. Am. Soc. Nephrol.18:1637-1647 (2007) and Liu et al., “Emerging role of fibroblast growthfactor 23 in a bone-kidney axis regulating systemic phosphatehomeostasis and extracellular matrix mineralization,” Curr. Opin.Nephrol. Hypertens. 16:329-335 (2007)). It has been suggested thatFGF-23 behaves as a counter regulatory hormone for 1,25(OH)₂D₃, whichmaintains phosphate balance in the presence of vitamin D-mediatedsuppression of parathyroid hormone and increased intestinal phosphateand calcium absorption. Low levels of FGF-23 are detected in circulationin normal individuals; however, levels are increased in response tophosphate loading, vitamin D administration, renal failure, and inhereditary and acquired hypophosphate homeostasis and mineralization.(See Liu and Quarles, “How Fibroblast Growth Factor 23 works,” J. Am.Soc. Nephrol. 18:1637-1647 (2007) and Stubbs et al., “Role of FibroblastGrowth Factor 23 in Phosphate Homeostasis and Pathogenesis of DisorderedMineral Metabolosm in Chronic Kidney Disease,” Seminars in Dialysis20:302-308 (2007)).

Phosphate homeostasis and excretion is of particular interest inagriculture. Phosphate is typically fed above the animal's requirementto promote growth in an animal, particularly a livestock. Circulatoryphosphate levels above the immediate needs of the animal are rapidlyexcreted by action of FGF-23. Not only is excess phosphate that isexcreted by the animal an environmental concern but excreted phosphateis also costly to the producer because of the high cost of phosphatesupplements used for animal growth. Discovery of means to improve theretention of phosphate by the animal would decrease the need to addexpensive phosphate to the animal's diet and would reduce phosphatecontamination of the environment from animal excreta. (See Ward,“Phosphorus-friendly transgenics,” Nature Biotechnology, 19:415-416(2001)).

Accordingly, there is a need for methods of altering the metabolism ofdietary phosphate in animals such to increase phosphate availability andabsorption, thereby reducing the amount of phosphate required foradministration in animals.

BRIEF DESCRIPTION OF THE DISCLOSURE

Briefly, the present disclosure is directed to an isolated polypeptidecomprising an amino acid sequence having at least 75% sequence identityto an amino acid sequence selected from the group consisting of SEQ IDNO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8,SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.

In another embodiment, the present disclosure is directed to a vaccinecomprising a polypeptide and a carrier protein. The polypeptidecomprises an amino acid sequence having at least 75% sequence identityto an amino acid sequence selected from the group consisting of SEQ IDNO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8,SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.

In another embodiment, the present disclosure is directed to a method ofeliciting an immune response in a livestock. The method comprisesintroducing into the livestock a polypeptide, wherein the polypeptidecomprises an amino acid sequence having at least 75% sequence identityto an amino acid sequence selected from the group consisting of SEQ IDNO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8,SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.

In yet another embodiment, the present disclosure is directed to amethod of altering metabolism of a dietary nutrient in a livestockoffspring. The method comprises inducing production of a maternalantibody by introducing a polypeptide into a fertile livestock female,wherein the polypeptide comprises an amino acid sequence having at least75% sequence identity to an amino acid sequence selected from the groupconsisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ IDNO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ IDNO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ IDNO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ IDNO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ IDNO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ IDNO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ IDNO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ IDNO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45, and fertilizing atleast one gamete of the livestock, wherein said maternal antibody istransferred via egg yolk, through the placenta, or via colostrum to thelivestock offspring, thereby altering the livestock offspring'smetabolism of the dietary nutrient.

In another embodiment, the present disclosure is directed to a method ofaltering phosphate metabolism in a livestock, the method comprisinginducing production of an antibody by introducing a polypeptide into thelivestock, wherein said antibody inhibits the action of FGF-23.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B, and 1C are graphs depicting, respectively, weight, plasmaphosphate, and bone ash results of passive anti-FGF-23 (FGF-1; SEQ IDNO: 1) chicks at the conclusion of a two week trial with each group oneither an adequate or deficient phosphate diet as analyzed in Example 1.As shown in FIG. 1A, * denotes significant difference between low (Lpi)and normal (Npi) dietary phosphate within antibody treatment. As shownin FIGS. 1B and 1C, differing letters denote significant differencebetween low and normal phosphate within antibody treatment. FCA iscontrol antibody; FGF-1 is antibody to SEQ ID NO: 1.

FIGS. 2A, 2B, and 2C are graphs depicting, respectively, weight, plasmaphosphate, and bone ash results of passive anti-FGF-23 (FGF-U; SEQ IDNO: 5) chicks at the conclusion of a two week trial with each group oneither an adequate (Npi) or deficient (Lpi) phosphate diet as analyzedin Example 1. As shown in FIGS. 2B and 2C, differing letters denotesignificant difference between low and normal phosphate within antibodytreatment. FCA is control antibody; FGF-1 is antibody to SEQ ID NO: 5.

FIG. 3 is a diagram of two epitopes of FGF-23 (FGF-23-3; SEQ ID NO: 12and FGF-23-C; SEQ ID NO: 46) used in Example 2.

FIG. 4A is a graph depicting the specificity of antibodies used inExample 2 to their respective peptides. For example, “3 on 3” meansantibody to FGF-23 peptide 3 (SEQ ID NO: 13) tested specifically forpeptide 3 (SEQ ID NO: 13).

FIG. 4B is a graph depicting the specificity of antibodies used inExample 2 to their respective regions on the native human recombinantFGF-23 protein molecule.

FIG. 5A is a graph depicting the plasma phosphate levels of chicks asanalyzed in Example 2. Differing letters denote significant differencebetween low and normal phosphate within antibody treatment.

FIG. 5B is a graph depicting the bone ash percentage of chicks asanalyzed in Example 2. Differing letters denote significant differencebetween low and normal phosphate within antibody treatment. Dietscontained either deficient (low Pi) or adequate (adequate Pi) inorganicphosphate. Control is control antibody; FGF-23-C is antibody to SEQ IDNO: 46 and FGF-23 is antibody to SEQ ID NO: 12.

FIG. 5C is a graph depicting the total weight gain (grams) of chicksfrom hens vaccinated to induce the passive transfer of anti-FGF-23antibodies to the chicks as analyzed in Example 2.

FIG. 6 is a graph depicting the bone ash percentage of chicks asanalyzed in Example 3. Differing letters denote significant differenceat p<0.05.

FIG. 7 is a graph depicting the bone ash percentage of chicks asanalyzed in Example 4. * indicates significant difference between lowand normal phosphate within antibody treatment. Low P and Normal P arediets of chicks fed deficient or adequate diets in inorganic phosphate,respectively. FGF-C, FGF-2, FGF-3, T, and W are passively transferredantibodies to SEQ ID NOS: 46, 7, 12, 20 and 16, respectively.

FIG. 8 is a graph depicting the total weight gain (grams) of chicks fromhens vaccinated to induce the passive transfer of anti-FGF-23 antibodiesto the chicks as analyzed in Example 4. * denotes significant differencebetween low and normal phosphate within antibody treatment. Low P andNormal P are diets of chicks fed deficient or adequate diets ininorganic phosphate, respectively. FGF-C, FGF-2, FGF-3, T, and W arepassively transferred antibodies to SEQ ID NOS: 46, 7, 12, 20 and 16,respectively.

FIG. 9 is a graph depicting the plasma phosphate levels of chicksvaccinated to induce the passive transfer of anti-FGF-23 antibodies tothe chicks as analyzed in Example 4. * indicates significant differencebetween low and normal phosphate within antibody treatment. Low P andNormal P are diets of chicks fed deficient or adequate diets ininorganic phosphate, respectively. FGF-C, FGF-2, FGF-3, T, and W arepassively transferred antibodies to SEQ ID NOS: 46, 7, 12, 20 and 16,respectively.

FIG. 10 is a graph depicting the two-week weight gain (W2) in grams ofchicks from hens vaccinated to induce the passive transfer ofanti-FGF-23 antibodies to the chicks as analyzed in Example 5. *indicates significant difference between low and normal phosphate withinantibody treatment. H and L represent chicks fed diet adequate (H) ordeficient (L) levels of inorganic phosphate. CFGF3, CFGFT, FGF3 and FGFTrepresent passively transferred antibodies to peptides of SEQ ID NOS:13, 21, 12 and 20, respectively.

FIG. 11 is a graph depicting the plasma phosphate levels of chicks fromhens vaccinated to induce the passive transfer of anti-FGF-23 antibodiesto the chicks as analyzed in Example 6. * indicates significantdifference between low and normal phosphate within antibody treatment. Hand L represent chicks fed diet adequate (H) or deficient (L) levels ofinorganic phosphate. CFGF3, CFGFT, FGF3 and FGFT represent passivelytransferred antibodies to peptides of SEQ ID NOS: 13, 21, 12 and 20,respectively.

DETAILED DESCRIPTION OF THE DISCLOSURE

The present disclosure is therefore directed to a method for reducingthe amount of a dietary nutrient, e.g., phosphate, required in alivestock diet. The method involves the development of an antibodyagainst one of the key molecules that promotes excretion of phosphate,FGF-23. According to some aspects of the present disclosure, thisantibody could be induced in the animal directly through vaccination.According to some aspects of the present disclosure, this antibody couldbe maternally derived, i.e., a maternal antibody, which is transferredto the offspring. As used herein, the term “maternal antibody” refers toan antibody produced during an immune response in a mother. Livestockwhose diets may be altered according to the methods of the presentdisclosure include avian (including chicken, turkey, duck, goose,peafowl, emu, pheasant, guinea, fowl, quail, among others), swine,sheep, cattle, and fish. For example, avian are suitable for the methodof the present disclosure since, in some embodiments, the methodinvolves the transfer of a maternal antibody to offspring. Avianmaternally transfer protective antibodies via the yolk of fertilizedeggs and the fertile embryo takes these maternal antibodies up duringincubation. (See Cook and Trott, “IgY-Immune component of eggs as asource of passive immunity for animals and humans,” World's PoultryScience Journal 66:215-226 (2010)). Industry has already successfullyused hen egg antibodies to alter inflammatory processes and promotegrowth in livestock. Fish maternal transfer is similar to avian, wheretransfer occurs via the egg yolk. The transfer of maternal antibody tothe offspring of species such as sheep, cattle and swine also occurs,however this transfer occurs during the first suckling period afterbirth, where the maternal antibody is transferred through the placentaand from the first milk (colostrum) to circulation by way of an “opengut.” In one embodiment, the present disclosure is therefore directed toa method of neutralization of FGF-23 using maternally transferredantibody altered dietary phosphate requirements using an establishedchick growth model. (See Biehl et al., “Activity of various hydroxylatedvitamin D3 analogs for improving phosphorus utilisation in chicksreceiving diets adequate in vitamin D3,” British Poultry Science,39:408-412 (1998)).

The methods of the present disclosure alter the metabolism of a dietarynutrient, e.g., phosphate, in a livestock offspring via anantibody-based method in which a fertile female livestock (e.g., alaying hen) is vaccinated with vaccine comprising an FGF-23 peptide.This peptide is based on an epitopic analysis of FGF-23. In general,according to the methods of the present disclosure, the anti-FGF-23peptide is injected into a fertile female livestock (e.g., a laying hen)to confer antibodies to the fertile eggs or offspring. The offspring,e.g., chicks, with the acquired antibodies have a decreased FGF-23response when fed a diet comprising phosphate, thereby causing morephosphate to be absorbed in the intestine and enhanced resorption in therenal system. This in turn reduces the amount of phosphate needed intheir diet and the amount of phosphate excreted in their waste.

According to another aspect of the present disclosure, a vaccine isprovided for controlling the dietary phosphate requirements oflivestock. The vaccine comprises an FGF-23 peptide. The vaccine may beused as part of a vaccination regimen for controlling phosphate dietaryrequirements in livestock, particularly chickens, swine, sheep, cattle,and fish, optionally in combination with vaccinations for the protectionagainst disease. Commercial poultry are typically vaccinated to protectthem against a variety of diseases including: Marek's disease, Newcastledisease, fowl pox, and avian encephalomyelitis. The vaccine of thepresent disclosure may be administered as part of the regimen used bycommercial poultry producers and could be properly timed such that bothmaternal antibody transfer plus the individual's own response to avaccine directly administered to the individual assure continuedcirculating levels of antibody to FGF-23 throughout the life of theanimal.

According to yet another aspect of the present disclosure, the method oftransferring maternal anti-FGF-23 antibodies to livestock offspring maybe used in combination with current technologies for meeting thephosphate requirements of livestock including inorganic phosphatedietary supplementation, phytase supplementation for breaking downphytate phosphate (the form of phosphate present in plant tissues, e.g.,corn and soy) for increased absorption, citric acid supplementation forincreasing phytate digestibility, and 1,25(OH)₂D₃ supplementation toincrease phosphate availability and absorption through the up-regulationof the sodium phosphate transporter 2B. Inorganic phosphate and phytaseare the most commonly used. While these supplements address the issue ofavailable phosphate, they do not influence phosphate retention orabsorption. The FGF-23 vaccine could be used in combination with theseexisting solutions to improve their efficacy. Ultimately, the presentdisclosure could significantly reduce or eliminate the amount ofphosphate fed to livestock, and reduce the amount of phosphate excretedby the animal, providing environmental and economic benefits.

The methods of the present disclosure include inducing the production ofantibodies to epitopes of the FGF-23 peptide (i.e., anti-FGF-23antibodies), which in some embodiments, may be passively transferred toan offspring. The anti-FGF-23 antibodies block the mechanism by whichFGF-23 increases the urinary excretion of phosphate. FGF-23 is secretedby osteocytes/osteoblasts in bone and connective tissue and is releasedinto the plasma in response to an increase in plasma phosphate, Pi,concentration. FGF-23 acts in the kidney, in that it inhibits renalreabsorption of phosphate in the kidney, mostly in the proximalconvoluted tubule. FGF-23 also inhibits 1-hydroxylase. 1-hydroxylase isresponsible for the conversion of calcidiol to calcitriol (thebiologically active form of vitamin D, which enhances intestinalphosphate absorption).

“Antibody” (Ab) and “antibodies” (Abs) refer to monoclonal antibodies(mAb (singular) or mAbs (plural)), polyclonal antibodies (pAbs(plural)), multispecific antibodies, recombinant antibodies, chimericantibodies (cAb; a polypeptide comprising all or a part of the heavy andlight chain variable regions of an antibody from one host species linkedto at least part of the antibody constant regions from another hostspecies), single chain antibodies, single domain antibodies, Fabfragments, F(ab′) fragments, Fab′-SH fragments, F(ab′)₂ fragments, Fdfragments, Fv fragments, single-chain Fv fragments (“scFv”),disulfide-linked Fv fragments (“sdFv”), an isolated complementaritydetermining region (CDR), and anti-idiotypic (“anti-Id”) antibodies, andfunctionally active, epitope-binding fragments (or antigenicallyreactive fragments) of any of the above. Immunoglobulin molecules can beof any type (for example, IgG, IgE, IgM, IgD, IgA and IgY), class (forexample, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or subclass. Antibodiesto the peptides disclosed herein for use in the context of the presentdisclosure may be made using a variety of different techniques known inthe art. For example, polyclonal and monoclonal antibodies may be raisedby immunizing a suitable subject (such as, for example, a rabbit, goat,mouse or other mammal) with an immunogenic preparation that contains asuitable immunogen. The immunogen may be enriched/purified and isolatedfrom a cell that produces it using affinity chromatography,immunoprecipitation or other techniques that are well known in the art.Alternatively, immunogen may be prepared using chemical synthesis usingroutine techniques known in the art (such as, for example, asynthesizer). The antibodies raised in the subject may then be screenedto determine if the antibodies bind to the immunogen (or a fragmentthereof, a variant thereof, or a fragment of a variant thereof).

The structures of chicken FGF-23, human FGF-23, pig FGF-23, cow FGF-23,and fish FGF-23 were studied, and multiple epitopes comprisingoligopeptides sequences were identified, sequenced, and synthesized.Sequences were retrieved, aligned, and compared for homology using acommercial database, e.g., UniProtKB protein database (human, chick,etc). Sequences may be analyzed for antigenicity, e.g., using the Markovmodel and/or propensity scale methods. Specifically, the sequences maybe analyzed for antigenicity using the BepiPred 1.0 server and the EPCESserver to determine antigenicity (two separate prediction engines forlikelihood to cause antibody production). Protein structure may also bedetermined using a commercial database, e.g., the PDBe database(3-dimensional protein structure database). A combination of theinformation derived from UniProtKB, antigen prediction servers, and 3Dstructure, enables determination and selection of sequences havingdesired properties, including, hydrophilicity, homology between species,and accessibility on the FGF-23 protein molecule. Once suitablesequences are selected, the peptides may be synthesized withoutmodifications and with sufficient purity, such as <98% purity inmilligram quantities by Genscript (Piscataway, N.J.).

According to some embodiments the oligopeptide epitope sequences includean amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8,SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48. Theseepitopes have the sequences as shown in Table 1:

TABLE 1 oligopeptide epitope sequences. SEQ Description ID Peptideof FGF-23 NO: Sequence Epitope  1 VDGAPHQT Human FGF-1  2 INGVPHQTChicken FGF-1  3 VDGSPQQT FGF-1 (Pig and Cow)  4 VRKSTART Fish FGF-1  5TLENGYDV FGF-U (Human, Chicken, Pig, and Cow)  6 LLENNRDV Fish FGF-U  7YPNASPLL Human FGF-2  8 FPNSSPLL Chicken FGF-2  9 YPDTSPLL Pig FGF-2 10YPNSSPLL Cow FGF-2 11 APNASPLV Fish FGF-2 12 AFLPGMNP Human FGF-3 13VFFPGMNP Chicken FGF-3 14 AFLPGTNP FGF-3 (Pig and Cow) 15 VFVVGQNVFish FGF-3 16 RDPLNVLK Human W 17 LDPHQILV Chicken W 18 GDPLSVLKW (Pig and Cow) 19 SDPHRVAV Fish W 20 RRHTRSAE Human T 21 HRNTRSADChicken T 22 RRHTRSAH Pig T 23 RRHTRSAH Cow T 24 HRDKRNQV Fish T 25GMNPPPYS NP-1 (Human and Chicken) 26 GTNPPPYA NP-1 (Pig and Cow) 27GQNVPQTS Fish NP-1 28 RNEIPLIH Human NP-2 29 RNEIPLFR Chicken NP-2 30RNEIPLLH Pig NP-2 31 RNEIPLPH Cow NP-2 32 TNTVPLER Fish NP-2 33 AKRAFLPGNP-3 (Human, Pig, and Cow) 34 TKQVFFPG Chicken NP-3 35 SRQVFVVGFish NP-3 36 NTPIPRR Human NP-4 37 FNTPEPHR Chicken NP-4 38 ATARPRRPig NP-4 39 AATARPRR Cow NP-4 40 LLHR Fish NP-4 41 TRSAEDDS Human NP-542 TRSADVDP Chicken NP-5 43 TRSAHDGG Pig NP-5 44 TRSAHDSG Cow NP-5 45KRNQVVDP Fish NP-5 46 QTIYSALMI FGF-C  (Human, Chicken, and Pig) 47QTVYSALMI Cow FGF-C 48 RTSYSVILL Fish FGF-C

The present disclosure encompasses the oligopeptide epitope sequenceslisted in Table 1 and epitope sequences of substantial homology.According to some embodiments, three amino acids may be changed suchthat the oligopeptide epitope sequence has 60% sequence identity to anamino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3,SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ IDNO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ IDNO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ IDNO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ IDNO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ IDNO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, and SEQID NO:48. According to some embodiments, two amino acids may be changedsuch that the oligopeptide epitope sequence has 75% sequence identity toan amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8,SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ IDNO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ IDNO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ IDNO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ IDNO:43, SEQ ID NO:44, SEQ ID NO:45, and SEQ ID NO:46, SEQ ID NO:47, andSEQ ID NO:48. According to some embodiments, one amino acid may bechanged such that the oligopeptide epitope sequence has about 85%sequence identity to an amino acid sequence selected from SEQ ID NO:1,SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ IDNO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ IDNO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ IDNO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ IDNO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ IDNO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ IDNO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ IDNO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ IDNO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, and SEQID NO:48. According to some embodiments, the oligopeptide epitopesequence is an amino acid sequence selected from SEQ ID NO:1, SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7,SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ IDNO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ IDNO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ IDNO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ IDNO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ IDNO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ IDNO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, and SEQID NO:48.

Techniques for determining amino acid sequence “identity” are well knownin the art. In general, “identity” means the exact amino acid to aminoacid comparison of two or more polypeptides at the appropriate place,where amino acids are identical or possess similar chemical and/orphysical properties such as charge or hydrophobicity. A so-termed“percent identity” may then be determined between the comparedpolypeptide sequences. Techniques for determining amino acid sequenceidentity also are well known in the art and include determining thenucleotide sequence of the mRNA for that gene (usually via a cDNAintermediate) and determining the amino acid sequence encoded therein,and comparing this to a second amino acid sequence. Two or more aminoacid sequences can be compared by determining their “percent identity”or “percent sequence identity”. The programs available, for example, theWisconsin Sequence Analysis Package, Version 8 (available from GeneticsComputer Group, Madison, Wis.) and the GAP program, are capable ofcalculating the identity between two polypeptide sequences. Otherprograms for calculating identity between sequences are known by thoseskilled in the art.

The FGF-23 oligopeptide epitope sequences may be used in the preparationof conjugate vaccines. According to some embodiments of the presentdisclosure, the isolated epitope may be conjugated with a carrierprotein and formulated into a vaccine. Suitable carrier proteins includebovine gamma globulin, FGF-23, bovine serum albumin, keyhole limpethemocyanin, ovalbumin, or any protein that, when conjugated with thepeptide, elicits an antibody to the attached peptide. According to someembodiments, the epitope may belong to a species other than thelivestock species, e.g., a human FGF-23 oligopeptide epitope, and thecarrier protein may be endogenous FGF-23. According to some embodiments,the entire sequence of FGF-23 could be used as a vaccine withoutconjugation.

The epitope sequence may be conjugated according to methods known in theart. In some embodiments, the epitope sequence may be conjugated to thecarrier protein via a glutaraldehyde linking moiety. In someembodiments, the epitope sequence may be conjugated to the carrierprotein via maleimide mediated conjugation. In some embodiments, theepitope sequence may be conjugated via1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC)mediated conjugation. Other methods of hatpen-carrier proteinconjugations could be used and the method of conjugation is not criticalas long as antibody to the desired peptide is effectively generated (seeCarter, Techniques for conjugation of synthetic peptides to carriermolecules, Methods Molecular Biology 36:155-191 (1994); Carter,Conjugation of peptides to carrier proteins via glutaraldehyde pp679-687, In Protein Protocols Handbook, eds J. M. Walker, Humana Press,Totowa, N.J.).

The conjugate vaccine comprising the FGF-23 epitope sequence and carrierprotein is prepared in an immunopotentiator, specifically animmunological adjuvant. Suitable adjuvants for preparing a conjugatevaccine according to the present disclosure include alum, aluminumphosphate, aluminum hydroxide, squalene, and oil-based adjuvantsincluding Freund's Complete and Incomplete adjuvant or others as listedin Cooper, P. D. (The selective induction of different immune responsesby vaccine adjuvants; Strategies in Vaccine Design. G. L. Ada, ed. R. G.Landes Company, Austin, Tex. (1994)). A specific adjuvant suitable forpreparing the conjugate vaccine according to the present disclosure isFreund's complete adjuvant. Another specific adjuvant suitable forpreparing the conjugate vaccine according to the present disclosure isFreund's incomplete adjuvant. Branded commercial adjuvants are alsoavailable and are suitable such as, for example, Titermax, AddaVax,Alhydrogel. In general, the concentration of the conjugated vaccine inthe adjuvant formulation generally ranges from about 50 micrograms toabout 6 milligrams, preferably between about 50 micrograms and about 3milligrams, even more preferably between about 50 micrograms and about 1milligram.

According to some methods of the present disclosure, a maternallivestock, e.g., a laying hen, is injected with the conjugate vaccinecomprising the FGF-23 oligopeptide epitope sequence conjugated to acarrier protein. The conjugate vaccine may be carried in an adjuvant,e.g., Freund's complete adjuvant. In some embodiments, the maternallivestock may be vaccinated in combination with a conventionalvaccination regimen. Injections may occur once or multiple times, e.g.,a secondary booster shot injected about one to two weeks after theprimary vaccination. The secondary booster shot may comprise the sameadjuvant or a different adjuvant, e.g., Freund's incomplete adjuvant.

The vaccination elicits an immune system response, which results in theproduction of antibodies against an endogenous protein, specifically,antibodies against endogenous FGF-23. The maternal livestock's (e.g.,laying hen) immune system recognizes the epitopes, which mobilizes thepreparation of maternal antibodies that recognize the FGF-23oligopeptide epitope sequence. In some embodiments, the epitopescomprise FGF-1, human and chicken FGF-3, W, human and chicken T, and/orFGF-U, whose structures are provided above.

According to the methods of the present disclosure, the maternalantibodies are transferred to the offspring. In some embodiments, thematernal livestock is poultry, e.g., a laying hen or fish, and thematernal antibodies are transferred via the egg yolk. The fertilizedembryo assumes the maternal antibodies during incubation. Maternalantibodies may be acquired from swine, sheep and cattle, wherein thematernal antibodies are acquired through the placenta or orally fromcolostrum. According to some embodiments, the passively transferredmaternal antibodies alter or block the function of an endogenousprotein, thereby altering the metabolism of a dietary nutrient in theoffspring. In some preferred embodiments, the passively transferredmaternal antibodies alter or block the function of FGF-23 in theoffspring, thereby decreasing the excretion of phosphate from the renalsystem and increasing the absorption of phosphate from the intestinallumen. Without being bound by theory, is currently believed that thepassively transferred maternal antibodies block the function of FGF-23by binding thereto. The plasma concentration of FGF-23 in the normal,fasting state is generally low. The plasma concentration increases viathe release from bone osteocytes in response to a meal comprisingphosphate. The passively transferred maternal antibodies bind to FGF-23in the blood plasma, thereby inhibiting its renal function. Theseeffects enable feeding the livestock offspring, e.g., a chick, a diethaving decreased phosphate concentration. In some embodiments, theamount of phosphate in the diet may be decreased at least 10 wt. %, atleast 25 wt. %, or even at least 50 wt. %, and the growing chicksachieve weight and bone densities comparable to chicks receiving a dietcomprising phosphate concentrations conventional in the industry.

In some embodiments, the vaccine including the FGF-23 oligopeptideepitope sequence conjugated to a carrier protein may be directlyinjected into livestock to induce active immunity. Particularly, animmune response in the livestock is elicited by introducing the vaccineinto the livestock. The initial administration can be followed by one ormore booster administrations of the vaccine.

In some embodiments, anti-FGF-23 antibody may be isolated andadministered to a livestock. Suitable methods for administering theantibody may be, for example, orally and parentally.

Certain technologies have been developed for meeting the phosphaterequirements of farm animals. These include dietary inorganic phosphate,phytase for breaking down phytate phosphate to increase its availabilityfor absorption, citric acid which increases phytate digestibility, and1α, 25 (OH)₂D₃ or analogue which also increases phosphate availabilityand absorption through the up-regulation of the sodium phosphatetransporter 2b. The vaccination method of the present disclosure may beused in combination with any or all of these technologies for meetingthe phosphate requirements of livestock. Inorganic phosphate and phytaseare widely used in animal agriculture. These supplements address theissue of available phosphate, but have no influence on phosphateretention, and just because it is available in the lumen of theintestine, it does not mean it will be absorbed. In fact, elevatedFGF-23 will decrease phosphate absorption even if it is more availablein the lumen. A method combining dietary inorganic phosphate, phytase,and the anti-FGF-23 antibodies described herein should improve thephosphate utilization in livestock, thereby enabling reduction in theamount of phosphate in the diet.

In some embodiments, the methods of the present disclosure may be usedin combination with citric acid and vitamin D supplementation. Theactive vitamin D products not only improve phytate phosphatebioavailability, they also increase absorption. Active vitamin D couldovercome the block in phosphate absorption caused by FGF-23, but it willnot affect retention at the level of the kidney.

The following examples illustrate specific embodiments within the scopeof the present disclosure. The examples are provided for the purpose ofillustration and are not to be construed as limitations of the presentdisclosure.

EXAMPLES Example 1

In this Example, the effect of altering the function of FGF-23 throughmaternally-derived antibody on the dietary phosphate requirements ofbaby chicks was analyzed.

Materials and Methods Conjugation of Selected Peptide and Injection

Bovine gamma globulin, a carrier protein, was dissolved in 0.1 molarsodium acetate buffer (5 mg/1 mL). 0.02M Glutaraldehyde was then addedto the selected peptide (0.13 mL per 1 mg peptide) and allotted 2-3hours to conjugate. The reaction was stopped after an hour by theaddition of 20 mg glycine (98%). Conjugated peptides were then dialyzedovernight in phosphate buffered saline solution at room temperature in6000-8000 molecular weight dialysis tubing.

The dialyzed, conjugated peptides were split into two aliquots forprimary and secondary booster vaccinations. The booster was stored in−80° C. freezer until use. Primary injection was prepared by emulsifyingthe peptide-carrier solution in Freund's complete adjuvant at a 1:1ratio. The emulsified peptides were then put into 3-ml syringes with21-gauge needles and laying hens were injected across four sites (breastand thigh muscle) with the vaccine to either an epitope of FGF-23peptide (FGF-1 (SEQ ID NO:1) or U (SEQ ID NO:5)) or the FCA control.Hens were boosted one week after primary vaccination as described aboveexcept Freund's incomplete adjuvant was used to emulsify the selectedpeptide or as control.

Experimental Animals

Three weeks after the primary vaccination, control or FGF-23 injectedhens were inseminated 1×/week for 2 weeks. Fertile eggs were collectedand incubated for 3 weeks, and the resulting chicks were randomly placedon a phosphate deficient or adequate diet.

To evaluate growth rates, chick weights were recorded at day zero(hatch) and then weekly. At the conclusion, chicks were bled via cardiacpuncture and then CO₂ euthanized. The right tibiotarsus was removed fordry, fat-free bone ash analysis. Blood samples were collected for plasmaphosphate analysis.

Mixing Diet

Two diets were mixed to accommodate deficient and adequate phosphatelevels, deficient in available inorganic phosphate and adequate inavailable inorganic phosphate. The compositions of these diets are shownin Table 2.

TABLE 2 Composition of Diets Adequate and Deficient in Phosphate, PiIngredient Deficient Pi Diet (%) Adequate Pi Diet (%) Base Mix* 96.696.6 CaCO₃ 0.48 0.96 KH₂PO₄ 0.6 1.20 Sand 2.32 1.24 Base Mix* g/100 gCorn 51.93 Soy 48 (soybean meal 48% protein) 40.50 Corn Oil 5.10 CaCO31.35 Salt 0.41 DL-Methionine 0.20 Vitamin-Mineral Mix 0.51 *Thedeficient and adequate diets contained 0.52% and 0.66% total and 0.28and 0.42 available phosphate (Pi), respectively.

Dry Fat-Free Bone Ash

Fat was removed from collected bones via ether extraction for 5 days.Bones were then ashed at 600° F. in a muffle furnace for 24 hours andash was determined from bone weights pre- and post-ashing in thefurnace.

Plasma Phosphate

Plasma samples were taken to the University of Wisconsin Veterinary Labfor phosphate analysis using a colorimetric method on a Hitachiautoanalyzer (Wisconsin Veterinary Diagnostic Laboratory, 445 EasterdayLn, Madison, Wis. 53706).

Statistical Analyses

Data were analyzed by analysis of variance as a 2×2 factorial withdietary phosphate and antibody type as main effects. Pairwisecomparisons were made using least square differences even ifinteractions were not statistically different. Treatment means wereconsidered different if p=0.05 or less. Difference with p=0.1 or lesswere described as trends in the results.

Results and Discussion Effects of Anti-FGF-23 on Growth

Chick weights of the treatment groups, over time are shown in FIGS. 1A,2A, and Table 3. Feeding chicks a deficient diet resulted in a 15%decrease in final body weight (main effect of diet p<0.01) in experiment1, but not in experiment 2 when compared to chicks fed an adequatephosphate diet. FGF-1 chicks had an 11% increase in final body weight(main effect of antibody p<0.09) when compared to the control antibodychicks in experiment 1, but not experiment 2. The decrease in bodyweight due to phosphate deficiency was prevented in deficient chicksreceiving passive anti-FGF-1, such that their final body weight did notdiffer from the chicks fed adequate levels of dietary phosphate. Chickswith passive FGF-1 also had heavier body weights at hatch than chickswith control passive antibody. Passive antibody to FGF-U had no effecton weight at hatch.

The ability of anti-FGF-1 to overcome growth depression due to phosphatedeficiency could be the result of the initial weight of chicks receivingpassive antibody to FGF-23. It is well known in the literature that theheavier a chick is at hatch, the faster the growth rate. (SeeSommerville et al., “The Time Sequence of Adaptive Changes to DietaryPhosphorus Deficiency in the Chick,” Horm. Metabol. Res. 17:247-250(1985)). Equally possible is that the neutralization of FGF-23 reducedthe phosphate requirements of the baby chick by reducing urinaryphosphate excretion and increasing intestinal phosphate absorption.

TABLE 3 Treatment means and p values for Experiment 1 and Experiment 2Plasma Trial Anti- Weight (g) Pi Bone No. body Diet Initial Week 1 Week2 (mg/dL) Ash (g) 1 FCA Npi 40.1^(bc) 65.5^(ab) 109.8^(ab) 5.7^(a)0.128^(ab) Lpi 39.9^(c) 59.6^(b) 93.2^(b) 3.0^(b) 0.105^(b) FGF-1 Npi43.6^(ab) 74.3^(a) 122.9^(a) 6.0^(a) 0.151^(a) Lpi 45.4^(a) 67.3^(ab)104.0^(ab) 3.8^(b) 0.134^(a) SEM 1.0 3.1 6.6 0.4 0.01 P values Diet 0.680.05 0.01 0.01 0.07 Ab 0.01 0.02 0.09 0.22 0.02 Diet x 0.22 0.87 0.870.52 0.77 Ab 2 FCA Npi 38.7^(ab) 59.1 96.3 5.1^(a) 0.126^(a) Lpi38.7^(ab) 59.1 89.7 3.4^(bc) 0.108^(ab) U Npi 36.7^(b) 56.3 100.34.7^(ab) 0.111^(ab) Lpi 40.1^(a) 59.8 93.6 2.2^(c) 0.097^(b) SEM 0.9 2.36.9 0.77 0.013 P values Diet 0.08 0.45 0.33 0.01 0.09 Ab 0.80 0.65 0.560.14 0.17 Diet x 0.04 0.45 0.99 0.46 0.83 Ab SEM = standard error of themean, Ab = antibody

Effects of Anti-FGF-23 on Plasma Phosphate Levels

Chicks fed the phosphate deficient diet (main effect of diet) hadreduced plasma phosphate (41% and 42% in experiments 1 and 2,respectively) when compared to chicks fed the diet adequate inphosphate. Anti-FGF-1 and anti-FGF-U was not effective at preventing thedecline in plasma phosphate due to phosphate deficiency (FIGS. 1B, 2B,and Table 2).

Anti-FGF-1 was effective at preventing decreases in body weight(discussed above) and bone ash (discussed below) if chicks were fed aphosphate deficient diet. However, the reduction in blood phosphateassociated with feeding a phosphate deficient diet was not preventedwhen the chicks received anti-FGF-1 antibodies. It is possible that thehighest priority of the baby chick for plasma phosphate is growth andbone formation; hence, plasma phosphate is the last clinical indicatorof inadequate phosphate to be restored. Indeed literature shows thatplasma phosphate is the first or most sensitive indices of marginallevels of dietary needs to ascertain the actual phosphate requirementsof chicks with anti-FGF-1 antibodies.

Effects of FGF-23 on Bone Ash Amounts

Bone ash was reduced 22% and 14% in experiments 1 and 2, respectively,when chicks were fed the phosphate deficient diet as compared to thephosphate adequate diet (main effect of diet, p=0.07 in experiment 1 andp=0.09 in experiment 2). The decrease in bone ash was prevented ifchicks had passive anti-FGF-1, such that chicks on the phosphatedeficient diet and passive anti-FGF-1 had bone ash equal to those fedthe phosphate adequate diets. Anti-FGF-U did not prevent the decrease inbone ash associated with feeding a phosphate deficient diet. Anti-FGF-1,but not anti-FGF-U, increased bone ash (main effect of antibody, p=0.02)when compared to chick with the control antibody.

Phosphate is an essential mineral for the synthesis of bone. It seemsreasonable that if blood phosphate was made available for bone formationthrough the inhibition of FGF-23, then bone ash would be increased.These data suggest that FGF-23, in response to dietary intake ofphosphate, may result in the over secretion of phosphate essential forbone development. The inability of FGF-U to increase bone phosphate maybe because it is ineffective at neutralizing plasma FGF-23. Anti-FGF-1'sability to result in normal bone ash on a phosphate deficient dietstrongly suggests that the phosphate requirement of chicks, where FGF-23is neutralized, is considerably lower than animal with intact FGF-23.Unlike wild birds, where seeds and insects can vary widely in theiravailable phosphate content, birds raised under agricultural conditionshave a constant supply of dietary phosphate. In the wild type diet,birds need a mechanism for excreting excess phosphate. In contrast,phosphate consumption of domestically fed animals can be rigidlycontrolled through diet formulation. Hence, one could question the valueof FGF-23 in the domestic fowl since it may over excrete blood phosphateand block phosphate absorption.

Conclusion

Results of the experiments conducted suggest that altering the functionof FGF-23 through maternally-derived antibody may reduce the dietaryphosphate requirements of the baby chick. The ability to regulate thephosphate requirement through a neutralization of FGF-23 is epitopespecific. Currently, the poultry industry uses 0.4 million tons of feedphosphate at a cost of $400 million in the United States alone. If avaccine could be developed that reduced the use of a limited supply offeed phosphate, and decreased the excretion of phosphate in theenvironment, a cost-effective solution for phosphate pollution ofsurface water would be available.

Example 2

In this Example, the effect of altering the function of FGF-23 throughmaternally-derived antibody on the dietary phosphate requirements ofbaby chicks was analyzed.

Peptide Antibody Production: Conjugation and Injection

Two epitopes of FGF-23, FGF-23-C (SEQ ID NO:46 (QTIYSALMI)) and FGF-23-3(SEQ ID NO:12) shown in FIG. 3, were used for this Example. Thesepeptides were individually conjugated to bovine gamma globulin (BgG,Sigma, St. Louis, Mo.) using glutaraldehyde conjugation similar toExample 1. Briefly, 2 mg of the carrier protein, BgG, was dissolved in0.1 molar acetate buffer 2 mg of each peptide was then added to thebuffer (1:1 peptide to carrier protein ratio), followed by 0.23 mL of 2M glutaraldehyde and allowed to conjugate for 3 h at room temperature.The reaction was stopped with 10 mg glycine for 1 h. Dialysis occurredovernight in 1 L PBS at room temperature using 6000-8000 molecularweight dialysis tubing. Three hens per peptide were injected using 0.33mg/hen/injection and yolks were freeze-dried for subsequent antibodyanalyses.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA was utilized to demonstrate the presence of the anti-FGF-23peptide antibodies in the yolks of eggs laid by vaccinated hens.Indirect ELISA methods were utilized except the antigen coated was 100μg/plate of ovalbumin (OVA) or peptide-specific (FGF-23-3 or FGF-23-C)OVA conjugate, and blocking was accomplished using a non-proteinblocking buffer (175 μl/well, Pierce Scientific, Rockford, Ill.). Asecond ELISA was run as described above, except native FGF-23 (humanrecombinant, Adipogen, San Diego, Calif.) or ovalbumin (OVA, PierceScientific, Rockford, Ill.) was used to coat the plate overnight (0.5mg/mL) instead of an OVA-peptide conjugate. After blocking, antibodiesto FGF-23-3, FGF-23-C, or FCA were incubated overnight at 1:1000dilution and secondary antibody, substrate, and stop solution were allapplied as described above. Primary antibodies applied to OVA were usedas blanks (negative control; indicator of non specific binding).

Experimental Animal Population

Single Comb White Leghorn laying hens injected with the above mentionedFGF-23 peptide conjugates or FCA control were artificially inseminatedonce a week for two consecutive weeks with pooled New Hampshire roostersemen after 21 days following the primary injection or within 2 monthsof any booster injection used. Fertile eggs were incubated for 21 days,hatched, divided into groups based on the hens' peptide injectiontreatment, and assigned to one of two diets (Table 4): Diet 1) Basal: noadded dietary phosphate (phosphate deficient with 0.13% availableinorganic phosphorus and 0.27% unavailable phytate phosphorus, where thechick requirement=0.40% available phosphorus), Diet 2) Basal+calcium andphosphorus in a balance ratio of 2:1 to meet dietary requirements.Chicks per treatment varied due to number of fertile eggs laid, set, andhatched per hen within each treatment group (see results for n/group).On day 14 on the experimental diets, chicks were weighed, bled for thedetermination of plasma phosphate, and the tibiotarsi were collectedfrom euthanized chicks for bone ash determination. To determine boneash, bones were ether extracted for 7 days to remove fat, dried, andthen ashed in a muffle furnace for 24 hours at 600° C. (Pattison,Poultry Diseases 6th ed. Edinburgh, New York, N.Y.,Elsevier/Butterworth-Heinemann 2008). Day 14 was used as the terminationdate to prevent severe phosphate deficient rickets and to assurecontinued presence of maternal antibody.

TABLE 4 Experimental Diet and Base Mix Composition Ingredient DeficientPi (%) Adequate Pi (%) Base Mix* 96.60 96.60 CaCO₃ — 0.96 KH₂PO₄ — 1.20Sand 3.40 1.24 Base Mix* g/100 g Corn 51.93 Soy 48 40.50 Corn Oil 5.10CaCO₃ 1.35 Salt 0.41 DL-Methionine 0.20 Vit-Min Mix 0.51 *Low and normalphosphate diets contained 0.52% and 0.66% total and 0.28 and 0.42available phosphate (Pi), respectively.

Data Analysis

Data were analyzed by using two-way ANOVA as a 2×3 factorial (two dietsand three antibody treatments) with SAS (SAS Institute, Inc., Cary,N.C.). Data were analyzed for main effects of diet, antibody and thediet X antibody interactions. Post-ANOVA analyses of mean treatmentdifferences were conducted if the diet X antibody interaction wassignificant (p<0.05) using least squared differences (plasma phosphateand bone ash percentage). Data are shown as mean±standard error of themean.

Results

Eggs collected from hens injected with control or their respectivepeptide conjugate were used in an ELISA assay to determine the transferof peptide specific antibody to the egg yolk. Egg yolk antibody dilutedas little as 1:1000 showed peptide specific binding when compared tocontrol antibody (FCA) or nonspecific peptide conjugate antibody (i.e.,FGF-23-C antibody on FGF-23-3 peptide or vice versa, FIG. 4A). WhenFGF-23 or FCA control antibodies were co-incubated with native FGF-23,both FGF-23 antibodies bound equally to native FGF-23, whereas controlantibody did not (FIG. 4B).

Following the artificial insemination procedures, eggs were collectedfrom the control and FGF-23 vaccinated hens. A total of 30, 41, and 39eggs were collected from the hens injected with the control, FGF-23-C,and FGF-23-3, respectively. No differences in the percent egg fertilityand hatch of fertile eggs was observed as a result of vaccine treatment.All chicks within a vaccine treatment group were divided equally andassigned to either the low or adequate phosphate diet: FCA control, 10chicks each for low and adequate phosphate diets; FGF-23-C, 12 and 11chicks for low and adequate phosphate diet, respectively; and FGF-23-3,18 chicks each for the low and adequate phosphate diet. After 2 weeks onthe dietary treatments, chicks fed the adequate phosphate diet acrossall vaccine treatment groups had similar levels of plasma phosphate;whereas those fed the low phosphate diet had dissimilar plasma phosphate(diet X vaccine interaction p<0.027, FIG. 5A).

Control chicks on a low phosphate diet had 43% less plasma phosphate ascompared to control chicks fed adequate phosphate (p=0.0032),anti-FGF-23-C chicks fed a low phosphate diet had a 50% reduction inplasma phosphate compared to anti-FGF-23-C chicks fed adequate phosphate(p<0.0001), whereas anti-FGF-23-3 chicks fed a low phosphate diet showedno significant decrease in plasma phosphate relative to anti-FGF-23-3chicks fed adequate phosphate (p=0.19). Chicks with circulatinganti-FGF-23-3 maternal antibodies and fed the low phosphate diet hadplasma phosphate that was increased 31% and 33% above chicks fed thesame diet but with circulating levels of control or anti-FGF-23-Cantibodies, respectively (p<0.05). Hens producing control, anti-FGF-23-Cand anti-FGF-23-3 antibodies had similar plasma phosphate levels(control=4.8 mg/dL±0.95; anti-FGF-23-C=4.4 mg/dL±0.98; anti-FGF-23-3=5.3mg/dL±0.40).

Percent bone ash was similar between vaccine treatment groups fed thephosphate adequate diet; however, a significant interaction between dietand maternal vaccination was observed (p>0.05, FIG. 5B). Controlantibody and anti-FGF-23-C antibody chicks fed the phosphate deficientdiet had a 21% (p=0.014) and 29% (p<0.001), respectively, reduction inbone ash percent when compared to relevant chicks fed adequate levels ofphosphate. However, chicks with maternal anti-FGF23-3 antibody did nothave a significantly reduced percent bone ash when fed a low phosphatediet and compared to anti-FGF-23-3 chicks fed adequate phosphate(p=0.44). Chicks with anti-FGF-23-3 maternal antibody and fed a lowphosphate diet had an 11% (p=0.19) and 20% (p=0.01) increase in bone ashpercent when compared to control and FGF-23-C chicks, respectively, fedthe low phosphate diet.

While chicks fed low phosphate had decreased weight gain regardless ofmaternal antibody type (main effect of diet, p=0.0006), there was noprotection against decreased weight gain due to maternal antibody source(interaction of diet X maternal antibody, p=0.65, FIG. 5C).

Conclusion

Chicks with circulatory anti-FGF-23-3 antibody and fed adequate levelsof phosphate did not have increased blood phosphate levels when comparedto control fed chicks. In addition, hens that were injected withFGF-23-3 (the peptide associated with reduced phosphate requirements inthe progeny) appeared to have normal plasma phosphate levels and healthwas not compromised as a result of the vaccine. These results suggestthat neutralizing antibodies to FGF-23, such as through vaccination ofthe peptide of SEQ ID NO:12, may reduce the dietary phosphaterequirements of the baby chicks.

Example 3

In this Example, the effect of altering the function of FGF-23 throughmaternally-derived antibody on the dietary phosphate requirements ofbaby chicks was analyzed.

The antibody to the FGF-23 peptide, FGF-1 (SEQ ID NO:1), was preparedand injected into three hens as described in Example 2. Separately,three hens were treated with control FCA. The hens were then inseminatedthree weeks post-injection, and eggs were collected for two weeks andset for incubation.

Hatched chicks were put on either a normal or low phosphate diet (seeTable 5) on the day of hatching and allowed to grow for two weeks.

TABLE 5 Experimental Diets Ingredient Deficient Pi (%) Adequate Pi (%)Base Mix* 96.60 96.60 CaCO₃ 0.48 0.96 KH₂PO₄ 0.6 1.20 Sand 2.32 1.24Base Mix* g/100 g Corn 51.93 Soy 48 40.50 Corn Oil 5.10 CaCO₃ 1.35 Salt0.41 DL-Methionine 0.20 Vit-Min Mix 0.51 *Low and normal phosphate dietscontained 0.52% and 0.66% total and 0.28 and 0.42 available phosphate(Pi), respectively.

Bone ash was measured as in Example 2. As shown in FIG. 6, chicks fed alow phosphate diet in the presence of FGF-1 were significantly differentfrom FCA control chicks fed a low phosphate diet, but not different thanFCA or FGF-1 chicks fed a normal phosphate diet (p<0.05).

Example 4

In this Example, the effect of altering the function of FGF-23 throughmaternally-derived antibodies on the dietary phosphate requirements ofthe baby chicks was analyzed.

Antibodies to the following FGF-23 peptides, FGF-2 (SEQ ID NO:7); FGF-3(SEQ ID NO:12); T (SEQ ID NO:20); W (SEQ ID NO:16) and FGF-C (SEQ IDNO:46), were prepared and injected into hens as described in Example 2.Three hens per peptide were treated. Three hens were separately treatedwith control FCA. The hens were then inseminated three weekspost-injection, and eggs were collected for two weeks and set forincubation.

Hatched chicks were put on either a normal or low phosphate diet (seeTable 6) on the day of hatching and allowed to grow for two weeks.

TABLE 6 Experimental Diets Ingredient Deficient Pi (%) Adequate Pi (%)Base Mix* 96.60 96.60 CaCO₃ 0.48 0.96 KH₂PO₄ 0.6 1.20 Sand 2.32 1.24Base Mix* g/100 g Corn 51.93 Soy 48 40.50 Corn Oil 5.10 CaCO₃ 1.35 Salt0.41 DL-Methionine 0.20 Vit-Min Mix 0.51 *Low and normal phosphate dietscontained 0.52% and 0.66% total and 0.28 and 0.42 available phosphate(Pi), respectively.

Bone ash, weight gain, and plasma phosphate were measured as in Example2. As shown in FIG. 7, chicks fed high phosphate diets consistently hadhigher bone ash percentages than chicks of the same treatment fed lowphosphate diets (main effect of diet, p<0.0001). Feeding T and FGF-3chicks low phosphate diets only resulted in non-significant 6.5% and6.6% decreases in bone ash as compared to T and FGF-3 chicks fed anormal phosphate diet (p=0.50). The FCA control chicks had a significant20.8% decrease in bone ash, as expected (p=0.03). Moreover W chicks had11.36% decrease in bone ash, FGF-C chicks had a 30% decrease, and FGF-2chicks showed a 22.2% decrease, as compared to their respective normalphosphate-fed groups (p=0.19, p=0.0038, p=0.03, respectively). Overall,the antibodies to peptides W, FGF-3, and T reduced the bone mass lostfrom a low phosphate diet, but FGF-3 and T exhibited the best success indoing so.

As shown in FIG. 8, feeding FGF-3 chicks a low phosphate diet resultedin a significant 25.14% decrease in final body weight versus normalphosphate (p=0.0008). Further, FCA control chicks fed a low phosphatediet did not have significantly reduced body weight gain as compared tonormal phosphate fed chicks, but their weights were overall reduced by16.7% (p=0.07).

As shown in FIG. 9, FCF-C and FCF-2 chicks fed a low phosphate diet hadthe largest percent decreases in plasma phosphate levels, with 56.59%and 46.5% decreases, respectively (p<0.0001). FGF-3 chicks fed lowphosphate diets showed the smallest decrease in plasma phosphate levels,with only 13.69% (p=0.1525). T and W had 32.04% and 26.15% decreases,respectively, versus normal phosphate (p<0.003). The FCA control chicksfed low phosphate diets showed a 42.51% decrease in plasma phosphatelevels (p=0.0011), which was substantially more than a majority of thetreated chicks.

Conclusion

As shown in this Example, maternal antibody can be used to neutralizeFGF-23 and decrease the phosphate requirements necessary for chicks togrow efficiently by reducing the amount of phosphate an animal excretes.Further, minimal differences are observed in bone ash percentages in theFGF-3 and T antibody groups, indicating that the chicks were able toprevent the loss of enough phosphate to maintain bone ash even on thelow phosphate diets.

Example 5

In this Example, the effect of altering the function of FGF-23 throughantibodies on the dietary phosphate requirements of the baby chicks wasanalyzed.

Antibodies to FGF-23 peptides, Chicken T (SEQ ID NO:21); Chicken FGF-3(SEQ ID NO: 13); FGF-3 (SEQ ID NO:12); and T (SEQ ID NO:20), wereprepared and injected into three hens as described in Example 2. Thehens were then inseminated three weeks post-injection, and eggs werecollected for two weeks and set for incubation.

Hatched chicks were put on either a normal or low phosphate diet (seeTable 7) on the day of hatching and allowed to grow for two weeks.

TABLE 7 Experimental Diets Ingredient Deficient Pi (%) Adequate Pi (%)Base Mix* 96.60 96.60 CaCO₃ 0.48 0.96 KH₂PO₄ 0.6 1.20 Sand 2.32 1.24Base Mix* g/100 g Corn 51.93 Soy 48 40.50 Corn Oil 5.10 CaCO₃ 1.35 Salt0.41 DL-Methionine 0.20 Vit-Min Mix 0.51 *Low and normal phosphate dietscontained 0.52% and 0.66% total and 0.28 and 0.42 available phosphate(Pi), respectively.

As shown in FIG. 10, weight reduction due to phosphate deficiency wasprotected with antibody to Chicken T, FGF-3, and T, but not ChickenFGF-3.

Example 6

In this Example, the effect of altering the function of FGF-23 throughantibodies on the plasma phosphate levels of the baby chicks wasanalyzed.

Antibodies to FGF-23 peptides, Chicken FGF-3 (SEQ ID NO:13); FGF-3 (SEQID NO:12); Chicken T (SEQ ID NO:21); and T (SEQ ID NO:20), were preparedand injected into three hens as described in Example 2. The hens werethen inseminated three weeks post-injection, and eggs were collected fortwo weeks and set for incubation.

Hatched chicks were put on either a normal or low phosphate diet (seeTable 8) on the day of hatching and allowed to grow for two weeks.

TABLE 8 Experimental Diets Ingredient Deficient Pi (%) Adequate Pi (%)Base Mix* 96.60 96.60 CaCO₃ 0.48 0.96 KH₂PO₄ 0.6 1.20 Sand 2.32 1.24Base Mix* g/100 g Corn 51.93 Soy 48 40.50 Corn Oil 5.10 CaCO₃ 1.35 Salt0.41 DL-Methionine 0.20 Vit-Min Mix 0.51 *Low and normal phosphate dietscontained 0.52% and 0.66% total and 0.28 and 0.42 available phosphate(Pi), respectively.

As shown in FIG. 11, Chicken FGF-3 provided protection against decreasedplasma phosphate during phosphate deficient feed.

This written description uses examples to disclose the invention,including the best mode, and also to enable any person skilled in theart to practice the invention, including making and using any devices orsystems and performing any incorporated methods. The patentable scope ofthe invention is defined by the claims, and may include other examplesthat occur to those skilled in the art. Such other examples are intendedto be within the scope of the claims if they have structural elementsthat do not differ from the literal language of the claims, or if theyinclude equivalent structural elements with insubstantial differencesfrom the literal languages of the claims.

What is claimed is:
 1. An isolated polypeptide comprising an amino acidsequence having at least 75% sequence identity to an amino acid sequenceselected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15,SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25,SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30,SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40,SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ IDNO:45.
 2. The isolated polypeptide of claim 1, wherein the amino acidsequence has at least 85% sequence identity to an amino acid sequenceselected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15,SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25,SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30,SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40,SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ IDNO:45.
 3. The isolated polypeptide of claim 1, wherein the amino acidsequence is selected from the group consisting of SEQ ID NO:1, SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9,SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24,SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39,SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44,and SEQ ID NO:45.
 4. A vaccine comprising a polypeptide comprising anamino acid sequence having at least 75% sequence identity to an aminoacid sequence selected from the group consisting of SEQ ID NO:1, SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9,SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24,SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39,SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44,and SEQ ID NO:45 and a carrier protein.
 5. The vaccine of claim 4,wherein the amino acid sequence has at least 85% sequence identity to anamino acid sequence selected from the group consisting of SEQ ID NO:1,SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ IDNO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.
 6. The vaccine of claim 4, wherein the aminoacid sequence is selected from the group consisting of SEQ ID NO:1, SEQID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ IDNO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.
 7. The vaccine of claim 4, wherein the carrierprotein is selected from the group consisting of bovine gamma globulin,FGF-23, bovine serum albumin, keyhole limpet hemocyanin, and ovalbumin.8. A method of eliciting an immune response in a livestock comprisingintroducing into the livestock a polypeptide, wherein the polypeptidecomprises an amino acid sequence having at least 75% sequence identityto an amino acid sequence selected from the group consisting of SEQ IDNO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8,SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.
 9. The method of claim 8, wherein thepolypeptide is conjugated to a carrier protein to form a conjugatedvaccine.
 10. The method of claim 8, wherein the livestock is an avian.11. The method of claim 8, wherein the livestock is a chicken, a turkey,a duck, a pheasant, a quail, a fish, a sheep, a swine, or a cattle. 12.The method of claim 8, wherein the polypeptide comprises an amino acidsequence having at least 85% sequence identity to an amino acid sequenceselected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10,SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15,SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25,SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30,SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40,SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ IDNO:45.
 13. The method of claim 8, wherein the polypeptide comprises anamino acid sequence selected from the group consisting of SEQ ID NO:1,SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ IDNO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ IDNO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ IDNO:44, and SEQ ID NO:45.
 14. A method of altering metabolism of adietary nutrient in a livestock offspring, the method comprising:inducing production of a maternal antibody by introducing a polypeptideinto an fertile livestock female, wherein the polypeptide comprises anamino acid sequence having at least 75% sequence identity to an aminoacid sequence selected from the group consisting of SEQ ID NO:1, SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9,SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24,SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39,SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44,and SEQ ID NO:45, and fertilizing at least one egg of the livestock,wherein said maternal antibody is transferred to the livestock offspringvia egg yolk, placenta or colostrum, thereby altering the livestockoffspring's metabolism of the dietary nutrient.
 15. The method of claim14, wherein the polypeptide is conjugated to a carrier protein to form aconjugated vaccine.
 16. The method of claim 15, wherein the conjugatedvaccine is introduced into the livestock in an amount between about 50micrograms and about 6 milligrams.
 17. The method of claim 14, whereinthe dietary nutrient is phosphate.
 18. A method of altering phosphatemetabolism in a livestock, the method comprising: inducing production ofan antibody by introducing a polypeptide into the livestock, whereinsaid antibody inhibits the action of FGF-23.
 19. The method of claim 18,wherein the polypeptide is conjugated to a carrier protein to form aconjugated vaccine.
 20. The method of claim 18 wherein the antibody is amaternal antibody, which is passively transferred to the livestock viaegg yolk, placenta or colostrum.
 21. The method of claim 18 whereinproduction of the antibody is induced by vaccination of the livestock.22. The method of claim 18 further comprising administering phytase tothe livestock.
 23. The method of claim 18 further comprising feeding thelivestock a diet comprising citric acid.